JGI iDEA Competitors

About Genomic Health Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care by addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ® Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 750,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the recently launched Oncotype SEQ® Liquid Select™ test. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn. About Oncotype DX® The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX Breast Recurrence Score®, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the Oncotype DX Breast DCIS Score™ predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. In prostate cancer, the Oncotype DX Genomic Prostate Score™ predicts disease aggressiveness and further clarifies the current and future risk of the cancer prior to treatment intervention. With more than 750,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeIQ.com, www.MyBreastCancerTreatment.org or www.MyProstateCancerTreatment.org.

Quantigen serves as both a contract research organization (CRO) and an active patient diagnostic laboratory. We employ a highly collaborative, cross-disciplinary approach when formulating the best strategy to meet each client’s unique translational needs. Our scientists, drawn from across academia, big pharma, and clinical laboratories, work in tandem during project planning and execution to deliver cutting-edge solutions: ones that ease the transition from bench to bedside. Whether performing diagnostic protocol optimization, biomarker development and validation, medical-device design, or early-phase clinical trials support, Quantigen leverages the insights of a diversely trained team to design projects that help to ensure a successful lab-to-clinic transfer process. For further information, contact us at: contact@quantigen.com.

BioVision is a privately held Life Science company headquartered in the beautiful San Francisco Bay area. BioVision aims to provide innovative, high quality research tools to accelerate drug discovery in disease-related areas like cancer, diabetes, obesity, Alzheimer's disease, etc. We achieve these goals through a well-defined core strategy and a company culture that fosters integrity, openness, and collaboration, and rewards customer focus. BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, etc. BioVision’s products are currently being sold in more than 60 countries worldwide.